Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Purpose: Patients with KRAS-mutant non–small cell lung cancer (NSCLC) with brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), a potent oral small-molecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib has been optimized for favorable pharmacokinetic properties, including long half-life (∼24 hours), extensive tissue distribution, dose-dependent pharmacokinetics, and central nervous system penetration; however, BM-specific antitumor activity of KRASG12C inhibitors remains to be fully characterized. Experimental Design: A retrospective database query identified patients with KRAS-mutant NSCLC to understand their propensity to develop BM. Preclinical studies assessed physiochemical and pharmacokinetic properties of adagrasib. Mice bearing intracranial KRASG12C-mutant NSCLC xenografts (LU99-Luc/H23-Luc/LU65-Luc) were treated with clinically relevant adagrasib doses, and levels of adagrasib in plasma, cerebrospinal fluid (CSF), and brain were determined along with antitumor activity. Preliminary clinical data were collected from 2 patients with NSCLC with untreated BM who had received adagrasib 600 mg twice daily in the phase Ib cohort of the KRYSTAL-1 trial; CSF was collected, adagrasib concentrations measured, and antitumor activity in BM evaluated. Results: Patients with KRAS-mutant NSCLC demonstrated high propensity to develop BM (≥40%). Adagrasib penetrated into CSF and demonstrated tumor regression and extended survival in multiple preclinical BM models. In 2 patients with NSCLC and untreated BM, CSF concentrations of adagrasib measured above the target cellular IC50. Both patients demonstrated corresponding BM regression, supporting potential clinical activity of adagrasib in the brain. Conclusions: These data support further development of adagrasib in patients with KRASG12C-mutant NSCLC with untreated BM. See related commentary by Kommalapati and Mansfield, p. 3179
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 1×
“Recent advances in targeted therapies, including next-generation EGFR and ALK tyrosine kinase inhibitors (TKI), suggest that CNS penetrant targeted therapies can lead to clinically meaningful activity in the CNS with improved safety profiles (11, 12).”
BackgroundRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“Oncogenic mutations in members of the RAS family are a common occurrence in human cancer, with alterations in KRAS accounting for 85% of these mutations (1).”
BackgroundHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 4×
“Adagrasib was optimized for desirable properties of a KRAS inhibitor, including favorable pharmacokinetic properties, such as oral bioavailability, long halflife ( 24 hours), dose-dependent pharmacokinetics, and extensive tissue distribution (23).”
BackgroundInfluentialSelf-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationFell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationTanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · cited 1×
“different genetic contexts guided by comutation of additional actionable genetic cancer drivers (such as CDKN2A deletion) will require exploration, to enhance efficacy and mitigate emergence of acquired resistance mechanisms (32, 33).”
BackgroundSelf-citationGoss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx820 · Cited by 247
Research works printed but not linked: 22
- Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study, J Med Life, 7, 581
- Offin, 2019, Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers, Cancer, 125, 4380, 10.1002/cncr.32461 · DOI
- Liu, 2019, Management of brain metastases: history and the present, Chin Neurosurg J, 5, 1, 10.1186/s41016-018-0149-0 · DOI
- Mehta, 2003, Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases, J Clin Oncol, 21, 2529, 10.1200/JCO.2003.12.122 · DOI · Paper page
- Cui, 2020, Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer, Lung Cancer, 146, 310, 10.1016/j.lungcan.2020.06.030 · DOI · Paper page
- Wu, 2021, Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation, Cancers, 13, 3572, 10.3390/cancers13143572 · DOI · Paper page
- Sebastian, 2021, KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315), Lung Cancer, 154, 51, 10.1016/j.lungcan.2021.02.005 · DOI · Paper page
- Lee, 2019, The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: a retrospective nationwide population-based cohort study, Sci Rep, 9, 18689, 10.1038/s41598-019-55150-6 · DOI
- Bauer, 2020, Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer, Target Oncol, 15, 55, 10.1007/s11523-020-00702-4 · DOI
- Soffietti, 2020, Management of brain metastases according to molecular subtypes, Nat Rev Neurol, 16, 557, 10.1038/s41582-020-0391-x · DOI · Paper page
- Ballard, 2016, Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399 · DOI · Paper page
- Kodama, 2014, Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases, Cancer Chemother Pharmacol, 74, 1023, 10.1007/s00280-014-2578-6 · DOI · Paper page
- Shaw, 2017, Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncol, 18, 1590, 10.1016/S1470-2045(17)30680-0 · DOI · Paper page
- Christensen, 2020, Targeting Kras(g12c) -mutant cancer with a mutation-specific inhibitor, J Intern Med, 288, 183, 10.1111/joim.13057 · DOI · Paper page
- Hu, 2018, Disease-causing mutations in the G protein galphas subvert the roles of GDP and GTP, Cell, 173, 1254, 10.1016/j.cell.2018.03.018 · DOI · Paper page
- Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 · DOI · Paper page
- Shimizu, 2022, Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice, Brain Res, 1774, 147706, 10.1016/j.brainres.2021.147706 · doi:10.1016/j.brainres.2021.147706
- Kiyokawa, 2021, Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma, Clin Cancer Res, 27, 889, 10.1158/1078-0432.CCR-20-2400 · DOI
- Miller, 2008, Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy, Pharmacol Rev, 60, 196, 10.1124/pr.107.07109 · DOI · Paper page
- Janne, 2019, A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors
- Sanchez-Cespedes, 2002, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung, Cancer Res, 62, 3659
- Shih, 2020, Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma, Nat Genet, 52, 371, 10.1038/s41588-020-0592-7 · DOI · Paper page
Cited by
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
Self-citationDhillon, S. (2023) · Drugs · doi:10.1007/s40265-023-01839-y · Cited by 161
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Metadata
- Authors
- Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., Rajan, A. P., Nieblas-Bedolla, E., Burns, A. C., Hallin, J., Olson, P., Christensen, J. G., Kurz, S. C., Brastianos, P. K., & Wakimoto, H.
- Venue
- Clinical Cancer Research
- Published
- 2022-04-11
- Volume
- 28
- Issue
- 15
- Pages
- 3318-3328
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4223491316
- Cited by
- 135
- References
- 10
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Mirati Therapeutics
- National Institute of Health (5R01CA227156-02)
- Damon Runyon Cancer Research Foundation
- Ben and Catherine Ivy Foundation
- Breast Cancer Research Foundation
- Demetra fund of the Hellenic Women's Association
- Terry and Jean de Gunzburg MGH Research Scholar Award
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-0383
- The paper
- Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., Rajan, A. P., Nieblas-Bedolla, E., Burns, A. C., Hallin, J., Olson, P., Christensen, J. G., Kurz, S. C., Brastianos, P. K., & Wakimoto, H. (2022). Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-0383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.